Possible involvement of the endocannabinoid system in the actions of three clinically used drugs
Possible involvement of the endocannabinoid system in the actions of three clinically used drugs
复制标题
DOI：
10.1016/j.tips.2003.12.001
复制
发表时间：
2004-02-01
影响因子：
13.8
通讯作者：
Fowler, CJ
中科院分区：
文献类型：
--
作者：
Fowler, CJ
人们对开发基于调节内源性大麻素系统的化合物来治疗多种疾病状态（例如疼痛、神经退行性变和癌症）的新疗法非常感兴趣。然而，最近对实验动物的研究证据表明，三种临床使用的药物，即麻醉剂异丙酚和非甾体抗炎药吲哚美辛和氟比洛芬（脊髓给药时），激活大麻素受体是其作用的重要组成部分。在本文中，总结了这些研究的结果，并讨论了这些药物可能的作用范围。
There is considerable interest in developing new therapies that are based on compounds that modulate the endocannabinoid system to treat several disease states (e.g. pain, neurodegeneration and cancer). However, recent evidence from studies in experimental animals has suggested that three clinically used drugs, the anaesthetic agent propofol and the non-steroidal anti-inflammatory drugs indomethacin and flurbiprofen (when given spinally), activate cannabinoid receptors as an important part of their actions. In this article, the findings of these studies are summarized and possible spectra of actions of these drugs are discussed.